The involvement of NF-κB p65/p52 in the effects of GDNF on DA neurons in early PD rats

Brain Research Bulletin

Volumn 76, Issue 5, 2008, Pages 505-511

  Cao, Jun Ping ^a   Wang, Hong Jun ^a   Yu, Jing Kao ^a   Liu, Hong Mei ^a   Gao, Dian Shuai ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Dopaminergic neurons; Early PD rat models; Glial cell line derived neurotrophic factor; NF B signaling pathway; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PROTEIN P50; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOPLASM; DOPAMINERGIC NERVE CELL; IMMUNOPRECIPITATION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CYTOLOGY; DISEASE MODEL; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; NEURONS; NF-KAPPA B P52 SUBUNIT; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TYROSINE 3-MONOOXYGENASE;

EID: 46349093562     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.03.007     Document Type: Article

References (38)

1. Bhakar A.L., Tannis L.L., Zeindler C., Russo M.P., Jobin C., Park D.S., MacPherson S., and Barker P.A. Constitutive nuclear factor-κB activity is required for central neuron survival. J. Neurosci. 22 (2002) 8466-8475
2. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends. Immunol. 25 6 (2004) 280-288
3. Borlongan C.V., Saporta S., Poulos S.G., Othberg A., and Sanberg P.R. Viability and survival of hNT neurons determine degree of functional recovery in grafted ischemic rats. NeuroReport 9 (1998) 2837-2842
4. Bui N.T., Livolsi A., Peyron J.F., and Prehn H.M. Activation of nuclear factor κB and bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IκBα. J. Cell. Biol. 152 (2001) 753-764
5. Chang C.F., Lin S.Z., Chiang Y.H., Morales M., Chou J., Lein P., Chen H.L., Hoffer B.J., and Wang Y. Intravenous administration of bone morphogenetic protein-7 after ischemia improves motor function in stroke rats. Stroke 34 (2003) 558-564
6. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., and Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 (1997) 838-847
7. Connor B., Kozlowski D.A., Unnerstall J.R., Elsworth J.D., Tillerson J.L., Schallert T., and Bohn M.C. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol. 169 1 (2001) 83-95
8. Daily D., Vlamis-Gardikas A., Offen D., Mittelman L., Melamed E., Holmgren A., and Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-κB via Ref-1. J. Biol. Chem. 276 (2001) 1335-1344
9. Fridmacher V., Kaltschmidt B., Goudeau B., Ndiaye D., Rossi F.M., Pfeiffer J., Kaltschmidt C., Israël A., and Mémet S. Forebrain-specific neuronal inhibition of nuclear factor-κB activity leads to loss of neuroprotection. J. Neurosci. 23 (2003) 9403-9408
10. Ghosh S., May M.J., and Kopp E.B. NF-k{cyrillic}B and REL proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998) 225-260
11. Gustin J.A., Korgaonkar C.K., Pincheira R., Li Q., and Donner D.B. Mechanisms of signal transduction: Akt regulates basal and induced processing of NF-κB2 (p100) to p52. J. Biol. Chem. 281 (2006) 16473-16481
12. Hamanoue M., Middleton G., Wyatt S., Jaffray E., Hay R.T., and Davies A.M. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol. Cell. Neurosci. 14 1 (1999) 28-40
13. Hattori N., and Mizuno Y. Pathogenesis of Parkinson's disease. Mol. Med. 38 (2001) 1236-1246
14. Hoffman A.F., van Horne C.G., Eken S., Hoffer B.J., and Gerhardt G.A. In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. Exp. Neurol. 147 1 (1997) 130-141
15. Henderson J.M., Annett L.E., Ryan L.J., Chiang W., Hidaka S., Torres E.M., and Dunnett S.B. Subthalamic nucleus lesions induce deficits as well as benefits in the hemiparkinsonian rat. Eur. J. Neurosci. 11 8 (1999) 2749-2757
16. Kalechman Y., Sredni B., Weinstein T., Freidkin I., Tobar A., Albeck M., and Gafter U. Production of the novel mesangial autocrine growth factors GDNF and IL-10 Is regulated by the immunomodulator AS101. J. Am. Soc. Nephrol. 14 (2003) 620-630
17. Kawasaki K., Smith R.S., Hsieh C.M., Sun J., Chao J., and Liao J.K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell. Biol. 23 (2003) 5726-5737
18. Kearns C.M., and Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672 1-2 (1995) 104-111
19. Kozlowski D.A., Connor B., Tillerson J.L., Schallert T., and Bohn M.C. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol. 166 1 (2000) 1-15
20. Liao G., and Sun S.C. Regulation of NF-κB2/p100 processing by its nuclear shuttling. Oncogene 22 (2003) 4868-4874
21. Lindner M.D., Gribkoff V.K., Donlan N.A., and Jones T.A. Long-lasting functional disabilities in middle-aged rats with small cerebral infarcts. J. Neurosci. 23 (2003) 10913-10922
22. Malek S., Huxford T., and Ghosh G. IκBα functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-κB. J. Biol. Chem. 273 (1998) 25427-25433
23. May M.J., and Ghosh S. Signal transduction through NF-kappa B. Immunol. Today 19 2 (1998) 80-88
24. Moorthy A.K., Savinova O.V., Ho J.Q., Wang V.Y., Vu D., and Ghosh G. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner. EMBO J. 25 9 (2006) 1945-1956
25. Nikkhah G., Falkenstein G., and Rosenthal C. Restorative plasticity of dopamine neuronal transplants depends on the degree of hemispheric dominance. J. Neurosci. 21 (2001) 6252-6263
26. Olsson M., Nikkhah G., Bentlage C., and Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15 (1995) 3863-3875
27. Paratcha G., Ledda F., and Ibanez C.F. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113 7 (2003) 867-879
28. Riederer P., and Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural. Trans. 38 3-4 (1976) 277-301
29. Sariola H., and Saarma M. Novel functions and signalling pathways for GDNF. J. Cell Sci. 116 (2003) 3855-3862
30. Sauer H., Rosenblad C., and Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor ß3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. PNAS 92 (1995) 8935-8939
31. Senftleben U., Cao Y., Xiao G., Greten F.R., Krähn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.C., and Karin M. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 293 (2001) 1495-1499
32. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., and Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21 (2001) 4427-4435
33. Treanor J.J., Goodman L., de Sauvage F., Stone D.M., Poulsen K.T., Beck C.D., Gray C., Armanini M.P., Pollock R.A., Hefti F., Phillips H.S., Goddard A., Moore M.W., Buj-Bello A., Davies A.M., Asai N., Takahashi M., Vandlen R., Henderson C.E., and Rosenthal A. Characterization of a multicomponent receptor for GDNF. Nature 382 6586 (1996) 80-83
34. Trupp M., Arenas E., Fainzilber M., Nilsson A.S., Sieber B.A., Grigoriou M., Kilkenny C., Grueso E.S., Pachnis V., Arumae U., Sariola H., Saarma M., and Ibanez C.F. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381 (1996) 785-789
35. Winkler C., Sauer H., Lee C.S., and Björklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16 (1996) 7206-7215
36. Wang C.Y., Mayo M.W., and Jr-Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
37. Wang H.J., Cao J.P., Yu J.K., and Gao D.S. Role of PI3-K/Akt pathway and its effect on glial cell line-derived neurotrophic factor in midbrain dopamine cells. Acta Pharmacol. Sin. 28 2 (2007) 166-172
38. Yasuhara T., Shingo T., Muraoka K., obayashi K.K., Takeuchi A., Yano A., Wenji Y., Kameda M., Matsui T., Miyoshi Y., and Date I. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J. Neurosurg. 102 1 (2005) 80-89